Loading clinical trials...
Loading clinical trials...
The Efficacy of Orally Administered GSK2190915 as an add-on to Current Therapy in Subjects With Moderate to Severe Asthma Who Have Elevated Sputum Neutrophils
Conditions
Interventions
GSK2190195 100mg
Placebo
Locations
8
Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Kingston, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Sainte-Foy, Quebec, Canada
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom
GSK Investigational Site
Leicester, Leicestershire, United Kingdom
Start Date
June 26, 2009
Primary Completion Date
June 2, 2010
Completion Date
June 2, 2010
Last Updated
November 30, 2020
NCT07219173
NCT02327897
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions